JNNP podcast

This month, getting a handle on aggressive multiple sclerosis. Suresh Menon and Helen Tremlett, both from the Department of Medicine, University of British Columbia, talk us through their recent step towards a definition of the disease.And Parkinson's patients who are disappointed after deep brain stimulation, despite gaining motor benefits and quality of life improvements. Catherine Lewis and Franziska Maier, both from the Department of Neurology, University of Cologne, explain how to predict who may end up feeling negative about the procedure, and how to support them.Read the papers:Characterising aggressive multiple sclerosis bit.ly/168RLWoPatients’ expectations of deep brain stimulation, and subjective perceived outcome related to clinical measures in Parkinson's disease: a mixed-method approach bit.ly/Hlup68

October's JNNP takes another step towards demystifying the relationship between sunlight, vitamin D, and MS, featuring a paper which reveals sun exposure may have direct effects on neurodegeneration independently of the vitamin.Murali Ramanathan, co-author of the study and professor of pharmaceutical sciences and neurology at the State University of New York at Buffalo, talks us through the research.Read the full paper, for free, here: bit.ly/171jo6N

October's JNNP takes another step towards demystifying the relationship between sunlight, vitamin D, and MS, featuring a paper which reveals sun exposure may have direct effects on neurodegeneration independently of the vitamin.Murali Ramanathan, co-author of the study and professor of pharmaceutical sciences and neurology at the State University of New York at Buffalo, talks us through the research.Read the full paper, for free, here: bit.ly/171jo6N

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on neurogenetics research and implications for practice from Nick Wood, professor of clinical neurogenetics, Institute of Neurology.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here: soundcloud.com/tags/abn%202013

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on neurogenetics research and implications for practice from Nick Wood, professor of clinical neurogenetics, Institute of Neurology.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here: soundcloud.com/tags/abn%202013

Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder with predilection for the optic nerves and spinal cord. Many recent advances, in particular, the discovery of NMO-IgG, an NMO-specific autoantibody, have furthered our understanding of the condition. Anu Jacob, consultant neurologist, The Walton Centre for Neurology and Neurosurgery, Liverpool, summarises what clinicians need to know in terms of diagnosing and treating NMO and its spectrum disorders.Read the full review, for free, here: http://goo.gl/fidlGL

Neuromyelitis optica (NMO) is an autoimmune inflammatory disorder with predilection for the optic nerves and spinal cord. Many recent advances, in particular, the discovery of NMO-IgG, an NMO-specific autoantibody, have furthered our understanding of the condition. Anu Jacob, consultant neurologist, The Walton Centre for Neurology and Neurosurgery, Liverpool, summarises what clinicians need to know in terms of diagnosing and treating NMO and its spectrum disorders.Read the full review, for free, here: http://goo.gl/fidlGL

This month, we get an update on the latest in clinically diagnosing the dementias, with a roundtable of experts convened by the Association of British Neurologists. Taking part are John Greene, Southern General Hospital, Glasgow, Chris Butler, Department of Clinical Neurology, University of Oxford, Nick Fox, Dementia Research Centre, UCL Institute of Neurology, and Huw Morris, Cardiff University School of Medicine.And using theory of mind deficits as an early marker of frontotemproal dementia. Matteo Pardini, Department of Neurosciences, University of Genoa, talks us through his research.See also:Isolated theory of mind deficits and risk for frontotemporal dementia: a longitudinal pilot study http://bit.ly/19figvN

This month, we get an update on the latest in clinically diagnosing the dementias, with a roundtable of experts convened by the Association of British Neurologists. Taking part are John Greene, Southern General Hospital, Glasgow, Chris Butler, Department of Clinical Neurology, University of Oxford, Nick Fox, Dementia Research Centre, UCL Institute of Neurology, and Huw Morris, Cardiff University School of Medicine.And using theory of mind deficits as an early marker of frontotemproal dementia. Matteo Pardini, Department of Neurosciences, University of Genoa, talks us through his research.See also:Isolated theory of mind deficits and risk for frontotemporal dementia: a longitudinal pilot study http://bit.ly/19figvN

We know that ALS is associated with executive dysfunction, but what about language deficits? Steven Wing, specialist neurology registrar at Addenbrooke’s Hospital, Cambridge, talks to Laura Goldstein, professor of Clinical Neuropsychology at the Institute of Psychiatry, about her recent paper investigating this.And anti-GQ1b antibody syndrome, or Bickerstaff brainstem encephalitis and Fisher syndrome. Editor Matthew Kiernan talks to Nobuhiro Yuki, Department of Medicine, National University of Singapore, about how the syndrome was first identified, and what we currently understand about it.See also:Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? http://bit.ly/1a6cRIzBickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome http://bit.ly/1aJrTmK

We know that ALS is associated with executive dysfunction, but what about language deficits? Steven Wing, specialist neurology registrar at Addenbrooke’s Hospital, Cambridge, talks to Laura Goldstein, professor of Clinical Neuropsychology at the Institute of Psychiatry, about her recent paper investigating this.And anti-GQ1b antibody syndrome, or Bickerstaff brainstem encephalitis and Fisher syndrome. Editor Matthew Kiernan talks to Nobuhiro Yuki, Department of Medicine, National University of Singapore, about how the syndrome was first identified, and what we currently understand about it.See also:Is language impairment more common than executive dysfunction in amyotrophic lateral sclerosis? http://bit.ly/1a6cRIzBickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome http://bit.ly/1aJrTmK

In Huntington’s disease the striatum takes a big hit early. This has prompted trials of foetal stratal transplantation, in the hope that this may provide some relief to patients.Stevan Wing, specialist neurology registrar at Addenbrooke’s Hospital, and researcher, University of Cambridge, speaks to Professor Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about his experience of leading a transplant trial with the NEST-UK consortium.See also:The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease http://jnnp.bmj.com/content/84/6/657.long

In Huntington’s disease the striatum takes a big hit early. This has prompted trials of foetal stratal transplantation, in the hope that this may provide some relief to patients.Stevan Wing, specialist neurology registrar at Addenbrooke’s Hospital, and researcher, University of Cambridge, speaks to Professor Roger Barker, John van Geest Centre for Brain Repair, University of Cambridge, about his experience of leading a transplant trial with the NEST-UK consortium.See also:The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington’s disease http://jnnp.bmj.com/content/84/6/657.long

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on multiple sclerosis research and implications for practice from Neil Robertson, professor of neurology, Cardiff University.They discuss new therapeutics BG-12 and alemtuzumab, the understanding of treatment risks, prognosis, prevalence and incidence, and MS and pregnancy.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here soundcloud.com/tags/abn%202013.

Ralph Gregory, secretary for the Association of British Neurologists and consultant neurologist in Dorset, gets an update on multiple sclerosis research and implications for practice from Neil Robertson, professor of neurology, Cardiff University.They discuss new therapeutics BG-12 and alemtuzumab, the understanding of treatment risks, prognosis, prevalence and incidence, and MS and pregnancy.This podcast is one of a series produced in collaboration with the Association of British Neurologists, of which there will be more to come over the next few months. You can find all the podcasts in the series here soundcloud.com/tags/abn%202013.